Compounded Tirzepatide in 2026: Dosage and Legal Status

Compounded tirzepatide is tirzepatide prepared by a compounding pharmacy rather than manufactured as an FDA-approved product. As of 2026 its status is very different from a year or two earlier: the drug-shortage conditions that once permitted widespread compounding have ended, and compounded tirzepatide remains not FDA-approved. This article explains, as general educational context, what compounded tirzepatide is, its legal status, why large-scale compounding stopped, and how dosing is approached. It is not medical advice, and it is not a statement about any specific product.

What is compounded tirzepatide?

Compounding is the practice of a licensed pharmacy preparing a medication to meet an individual patient’s needs. Compounded tirzepatide is therefore made by a pharmacy, not produced and tested as the branded products are. According to the FDA, compounded drugs are not FDA-approved, which means the agency does not verify their safety, effectiveness, or quality before they are marketed. The branded tirzepatide products — Zepbound (approved for chronic weight management and obstructive sleep apnea) and Mounjaro (approved for type 2 diabetes) — are FDA-approved and should not be conflated with compounded versions.

Is compounded tirzepatide legal in 2026?

Compounding itself is legal and regulated, but the conditions that allowed tirzepatide to be compounded at scale have ended. During the national shortage, pharmacies were permitted to compound copies of the drug. That changed when the shortage resolved: the FDA removed tirzepatide from its drug-shortage list in October 2024, and the semaglutide shortage was declared resolved in February 2025. With supply stabilizing, the agency has since clarified its policies for compounders, and the temporary grace periods for mass compounding ended in 2025. In general, a pharmacy may still compound a drug for an individual patient under specific circumstances, but routine large-scale production of tirzepatide copies is no longer permitted.

When	What changed
October 2024	FDA removed tirzepatide from the drug-shortage list
February 2025	Semaglutide shortage declared resolved
By 2025	Grace periods for large-scale GLP-1 compounding ended; mass compounding no longer permitted
2026	FDA clarified compounding policies as national GLP-1 supply stabilized

Because rules are specific and evolving, anyone considering compounded tirzepatide should confirm the current legal and clinical picture with a licensed provider and pharmacy rather than rely on a general article.

Why did large-scale compounding stop?

Compounding copies of an approved drug is broadly allowed only when that drug is in shortage. Once the FDA determined the shortage was over, the legal basis for widespread compounding fell away. The agency has also repeatedly raised quality concerns about compounded GLP-1 products — including the use of ingredients not suitable for sterile injection and dosing errors — which is part of why it encourages patients to use FDA-approved products obtained through a licensed clinician where possible. If you are comparing options, our guides to the tirzepatide dosage chart and tirzepatide vs semaglutide explain how the approved products are used.

How is compounded tirzepatide dosed?

There is no official, FDA-approved dosing for compounded tirzepatide, because the compounded form is not an approved product. Any dosing is determined individually by a licensed provider. For reference, the FDA-approved tirzepatide labels start at 2.5 mg injected under the skin once weekly for the first 4 weeks — a starting dose meant for initiation, not maintenance — and increase in 2.5 mg steps no more often than every 4 weeks, up to a maximum of 15 mg weekly. These are label references for the branded products, not recommendations for a compounded preparation, and you should never self-dose. Slow titration is used to reduce gastrointestinal side effects; see our overview of tirzepatide side effects for what to expect.

Is compounded tirzepatide safe?

Because compounded tirzepatide is not FDA-approved, its safety, quality, and potency are not verified by the FDA, and products can vary between pharmacies. The general risks of tirzepatide — nausea, vomiting, diarrhea, constipation, and the boxed warning regarding thyroid C-cell tumors seen in rodents — still apply, and compounding adds the further uncertainty of an unverified preparation. A licensed provider can weigh whether tirzepatide is appropriate for you and discuss FDA-approved options. Individual results and risks vary.

Frequently asked questions

Is compounded tirzepatide the same as Zepbound or Mounjaro?

No. Zepbound and Mounjaro are FDA-approved branded tirzepatide products that are reviewed for safety, quality, and effectiveness. Compounded tirzepatide is prepared by a pharmacy, is not FDA-approved, and is not reviewed by the FDA before it is sold, so it should not be considered equivalent.

Is compounded tirzepatide still available in 2026?

The conditions that allowed large-scale compounding ended after the FDA declared the tirzepatide shortage resolved in October 2024 and tightened its policies. Compounding for an individual patient may still occur under specific circumstances, but routine mass production of tirzepatide copies is no longer permitted. Check current availability and legality with a licensed provider.

What dose of compounded tirzepatide should I take?

There is no FDA-approved dose for compounded tirzepatide. Dosing must be determined by a licensed provider. For reference, branded tirzepatide labels start at 2.5 mg weekly and increase no faster than every 4 weeks to a maximum of 15 mg; never self-dose or adjust without medical guidance.

Why is compounded tirzepatide cheaper than branded?

Compounded preparations are not FDA-approved manufactured products and have historically been marketed at lower cash prices, but lower cost does not mean equivalent quality or safety, since compounded drugs are not FDA-verified. Cost should not be the deciding factor for a prescription medication; discuss value and safety with a licensed provider.

Is compounded tirzepatide FDA-approved?

No. No compounded drug is FDA-approved. The FDA does not review compounded tirzepatide for safety, quality, or effectiveness before it is sold. Only the branded products are FDA-approved.